Selank

Selank is a synthetic peptide derived from tuftsin, a naturally occurring immunomodulatory tetrapeptide, with an added proline-glycine-proline sequence intended to improve enzymatic stability. Developed in Russia, it has been studied primarily as an anxiolytic with reported mild nootropic properties, positioned in that research tradition as an alternative to benzodiazepines that does not appear to cause sedation or dependence in available studies. Research includes small clinical trials for generalized anxiety and adjustment-related symptoms conducted largely in Russian populations, with limited independent replication elsewhere. It is not approved for medical use in the United States and is available mainly as a research compound. As with related peptides in this class, human data remain preliminary and warrant cautious interpretation. Reported benefits include studied for anxiolytic effects without apparent sedation, explored for mild nootropic effects on attention and mental stamina, reported to support stress resilience in some research settings.

Reported ranges run 250-750 mcg. A low protocol is 250 mcg once daily, and a high protocol is 750 mcg split into two daily doses. This is reference information, not a dosing recommendation.

Reported to be short, on the order of minutes to roughly an hour in plasma, though downstream neurochemical effects may persist longer than the peptide's detectable presence.. That is what sets the dosing frequency, and it is why the timing guidance is morning.

Subcutaneous: into fat, under the skin. Historically administered intranasally in Russian clinical and research use; this profile reflects subcutaneous injection as used in current research contexts.

4-8 weeks on, followed by 2-4 weeks off. No controlled studies have established an optimal cycling schedule; breaks are discussed informally to limit theoretical tolerance.

Reported side effects include injection site reactions with subcutaneous use, mild headache reported in some users, limited data on long-term or high-dose safety, possible interaction with other central nervous system-acting compounds. Evidence level for this compound is well studied.